These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8784658)

  • 1. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients.
    Kim YH; Cha IJ; Shim JC; Shin JG; Yoon YR; Kim YK; Kim JI; Park GH; Jang IJ; Woo JI; Shin SG
    J Clin Psychopharmacol; 1996 Jun; 16(3):247-52. PubMed ID: 8784658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
    Suzuki A; Yasui-Furukori N; Mihara K; Kondo T; Furukori H; Inoue Y; Kaneko S; Otani K
    Ther Drug Monit; 2003 Apr; 25(2):192-6. PubMed ID: 12657913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
    Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
    J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
    Hesslinger B; Normann C; Langosch JM; Klose P; Berger M; Walden J
    J Clin Psychopharmacol; 1999 Aug; 19(4):310-5. PubMed ID: 10440457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels.
    Altamura CA; Colacurcio F; Mauri MC; Moro AR; De Novellis F
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):25-35. PubMed ID: 1967847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice.
    Yasui N; Kondo T; Suzuki A; Otani K; Mihara K; Furukori H; Kaneko S; Inoue Y
    Int Clin Psychopharmacol; 1999 Mar; 14(2):113-8. PubMed ID: 10220126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol.
    Mihara K; Otani K; Yasui N; Ishida M; Kondo T; Suzuki A; Furukori H; Nagashima U; Kaneko S; Inoue Y
    Ther Drug Monit; 1999 Jun; 21(3):297-300. PubMed ID: 10365640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-administration of sertraline and haloperidol.
    Lee MS; Han CS; You YW; Kim SH
    Psychiatry Clin Neurosci; 1998 Dec; 52 Suppl():S193-8. PubMed ID: 9895145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No interaction between desipramine and bromperidol.
    Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 Oct; 20(7):1265-71. PubMed ID: 8938825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
    Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
    J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol.
    Suzuki Y; Someya T; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
    Ther Drug Monit; 2001 Aug; 23(4):363-8. PubMed ID: 11477317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics.
    Gattaz WF; Rost W; Hübner CK; Bauer K
    Biol Psychiatry; 1989 Feb; 25(3):247-55. PubMed ID: 2643996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.
    Yasui N; Kondo T; Otani K; Furukori H; Mihara K; Suzuki A; Kaneko S; Inoue Y
    J Clin Psychopharmacol; 1999 Apr; 19(2):149-54. PubMed ID: 10211916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlates of rapid neuroleptic response in male patients with schizophrenia.
    Petrie EC; Faustman WO; Moses JA; Lombrozo L; Csernansky JG
    Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between carbamazepine and bromperidol.
    Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Eur J Clin Pharmacol; 1997; 52(3):219-22. PubMed ID: 9218929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
    J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.